Acadia_Pharmaceuticals_JPM2025_FINAL.pdf

1、43rd Annual JP Morgan Healthcare ConferenceCatherine Owen AdamsChief Executive OfficerJanuary 14,2025This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Forward-looking statements include all statements other than statement

2、s of historical fact and can be identified by terms such as“may,”“will,”“should,”“could,”“would,”“expects,”“plans,”“anticipates,”“believes,”“estimates,”“projects,”“predicts,”“outlook,”“potential”and similar expressions(including the negative thereof)intended to identify forward-looking statements.Fo

3、rward-looking statements contained in this presentation,include,but are not limited to,statements about:(i)our business strategy,objectives and opportunities;(ii)plans for,including timing,development and progress of commercialization or regulatory timelines for,NUPLAZID,DAYBUE and our product candi

4、dates;(iii)benefits to be derived from and efficacy of our products,including the potential advantages of NUPLAZID and DAYBUE and expansion opportunities for NUPLAZID and DAYBUE in other indications,and for DAYBUE in jurisdictions outside the U.S.and Canada;(iv)estimates regarding the prevalence of

5、the diseases targeted by our products and product candidates;(v)potential markets for any of our commercial products;and(vi)our estimates regarding our future financial performance,cash position,profitability or capital requirements.Forward-looking statements are subject to known and unknown risks,u

6、ncertainties,assumptions and other factors that may cause our actual results,performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements.Such risks,uncertainties and other factors include,but are not limited to:our dependency on